Trials of interventions for delirium in various patient populations report disparate outcomes and measures but little is known about those used in palliative care trials. A core outcome set promotes consistency of outcome selection and measurement.
Aim:
To inform core outcome set development by examining outcomes, their definitions, measures and time-points in published palliative care studies of delirium prevention or treatment delirium interventions.
Design:
Prospectively registered systematic review adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Data sources:
We searched six electronic databases (1980–November 2020) for original studies, three for relevant reviews and the International Clinical Trials Registry Platform for unpublished studies and ongoing trials. We included randomised, quasi-randomised and non-randomised intervention studies of pharmacological and non-pharmacological delirium prevention and/or treatment interventions.
Results:
From 13/3244 studies (2863 adult participants), we identified 9 delirium-specific and 13 non-delirium specific outcome domains within eight Core Outcome Measures in Effectiveness Trials (COMET) taxonomy categories. There were multiple and varied outcomes and time points in each domain. The commonest delirium specific outcome was delirium severity (n = 7), commonly using the Memorial Delirium Assessment Scale (6/8 studies, 75%). Four studies reported delirium incidence. Non-delirium specific outcomes included mortality, agitation, adverse events, other symptoms and quality of life.
Conclusion:
The review identified few delirium interventions with heterogeneity in outcomes, their definition and measurement, highlighting the need for a uniform approach. Findings will inform the next stage to develop consensus for a core outcome set to inform delirium interventional palliative care research.
WattCLMomoliFAnsariMT, et al. The incidence and prevalence of delirium across palliative care settings: a systematic review. Palliat Med2019; 33: 865–877.
2.
AgarMR.Delirium at the end of life. Age Ageing2020; 49(3): 337–340.
3.
AgarMRQuinnSJCrawfordGB, et al. Predictors of mortality for delirium in palliative care. J Palliat Med2016; 19: 1205–1209.
4.
LawlorPGDavisDHJAnsariM, et al. An analytical framework for delirium research in palliative care settings: integrated epidemiologic, clinician-researcher, and knowledge user perspectives. J Pain Symptom Manag2014; 48: 159–175.
5.
TunisSRClarkeMGorstSL, et al. Improving the relevance and consistency of outcomes in comparative effectiveness research. J Comp Eff Res2016; 5: 193–205.
6.
KirkhamJJGorstSAltmanDG, et al. Core outcome Set-STAndards for reporting: the COS-STAR statement. PLoS Med2016; 13: e1002148.
7.
BigganeAMBradingLRavaudP, et al. Correction to: survey indicated that core outcome set development is increasingly including patients, being conducted internationally and using Delphi surveys. Trials2018; 19: 430.
8.
TugwellPBoersMBrooksP, et al. OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials2007; 8: 38.
9.
HarropEScottHSivellS, et al. Coping and wellbeing in bereavement: two core outcomes for evaluating bereavement support in palliative care. BMC Palliat Care2020; 19: 29.
10.
BaddeleyEBravingtonAJohnsonM, et al. Development of a core outcome set to use in the research and assessment of malignant bowel obstruction: protocol for the RAMBO study. BMJ Open2020; 10: e039154.
11.
ZambranoSCHaugenDFvan der HeideA, et al. Development of an international core outcome set (COS) for best care for the dying person: study protocol. BMC Palliat Care2020; 19: 184.
12.
BoersMTugwellPFelsonDT, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol1994; 41: 86–89.
13.
KirkhamJJClarkeMWilliamsonPR.A methodological approach for assessing the uptake of core outcome sets using ClinicalTrials.gov: findings from a review of randomised controlled trials of rheumatoid arthritis. BMJ2017; 357: j2262.
14.
RoseLAgarMBurryLD, et al. Development of core outcome sets for effectiveness trials of interventions to prevent and/or treat delirium (Del-COrS): study protocol. BMJ Open2017; 7: e016371.
15.
MoherDLiberatiATetzlaffJ, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med2009; 6: e1000097.
16.
LawlorPGRutkowskiNAMacDonaldAR, et al. A scoping review to map empirical evidence regarding key domains and questions in the clinical pathway of delirium in palliative care. J Pain Symptom Manag2019; 57: 661–681.e12.
17.
HarmanNLBruceIACalleryP, et al. MOMENT—management of otitis media with effusion in cleft palate: protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. Trials2013; 14: 70.
18.
The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions version 5.1.0. [updated March 2011]. The Cochrane Collaboration, 2011. www.handbook.cochrane.org
19.
SterneJAHernánMAReevesBC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ2016; 355: i4919.
20.
RoseLAgarMBurryL, et al. Reporting of outcomes and outcome measures in studies of interventions to prevent and/or treat delirium in the critically ill: a systematic review. Crit Care Med2020; 48: e316–e324.
21.
DoddSClarkeMBeckerL, et al. A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. J Clin Epidemiol2018; 96: 84–92.
22.
BrueraEHuiDDalalS, et al. Parenteral hydration in patients with advanced cancer: a multicenter, double-blind, placebo-controlled randomized trial. J Clin Oncol2013; 31: 111–118.
23.
AgarMRLawlorPGQuinnS, et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Intern Med2017; 177: 34–42.
24.
LinC-JSunF-JFangC-K, et al. An open trial comparing haloperidol with olanzapine for the treatment of delirium in palliative and hospice center cancer patients. J Intern Med Taiwan2008; 19: 346–354.
25.
HuiDFrisbee-HumeSWilsonA, et al. Effect of lorazepam with haloperidol vs haloperidol alone on agitated delirium in patients with advanced cancer receiving palliative care: a randomized clinical trial. JAMA2017; 318: 1047–1056.
26.
DaviesANWaghornMWebberK, et al. A cluster randomised feasibility trial of clinically assisted hydration in cancer patients in the last days of life. Palliat Med2018; 32: 733–743.
27.
HosieAPhillipsJLamL, et al. A multicomponent nonpharmacological intervention to prevent delirium for hospitalized people with advanced cancer: a phase II cluster randomized waitlist controlled trial (the PRESERVE pilot study). J Palliat Med2020; 23: 1314–1322.
28.
LawlorPGMcNamara-KilianMTMacDonaldAR, et al. melatonin to prevent delirium in patients with advanced cancer: a double blind, parallel, randomized, controlled, feasibility trial. BMC Palliat Care2020; 19: 163–217.
29.
Van der VorstMJDLNeefjesECWBoddaertMSA, et al. Olanzapine versus haloperidol for treatment of delirium in patients with advanced cancer: a phase III randomized clinical trial. Oncologist2020; 25: e570–e577.
30.
MoritaTTeiYInoueS.Agitated terminal delirium and association with partial opioid substitution and hydration. J Palliat Med2003; 6: 557–563.
31.
GagnonPAllardPGagnonB, et al. Delirium prevention in terminal cancer: assessment of a multicomponent intervention. Psychooncology2012; 21: 187–194.
32.
BoettgerSBreitbartWPassikS.Haloperidol and risperidone in the treatment of delirium and its subtypes. Eur J Psychiatry2011; 25: 59–67.
33.
BoettgerSFriedlanderMBreitbartW, et al. Aripiprazole and haloperidol in the treatment of delirium. Aust N Z J Psychiatr2011; 45: 477–482.
34.
AraiYCNishiharaMKobayashiK, et al. Neurolytic celiac plexus block reduces occurrence and duration of terminal delirium in patients with pancreatic cancer. J Anesth2013; 27: 88–92.
35.
BushSHLacaze-MasmonteilNMcNamara-KilianMT, et al. The preventative role of exogenous melatonin administration to patients with advanced cancer who are at risk of delirium: study protocol for a randomized controlled trial. Trials2016; 17: 399.
36.
HosieAPhillipsJLamL, et al. Multicomponent non-pharmacological intervention to prevent delirium for hospitalised people with advanced cancer: study protocol for a phase II cluster randomised controlled trial. BMJ Open2019; 9: e026177.
37.
DaviesAWaghornMBoyleJ, et al. Alternative forms of hydration in patients with cancer in the last days of life: study protocol for a randomised controlled trial. Trials2015; 16: 464.
38.
BolandJWKabirMBushSH, et al. Delirium management by palliative medicine specialists: a survey from the association for palliative medicine of Great Britain and Ireland. BMJ Support Palliat Care. Epub ahead of print 4 March 2019. DOI: 10.1136/bmjspcare-2018-001586
39.
BushSHLawlorPGRyanK, et al. Delirium in adult cancer patients: ESMO clinical practice guidelines. Ann Oncol2018; 29(Suppl 4): iv143–iv165.
40.
GagnonPCharbonneauCAllardP, et al. Delirium in advanced cancer: a psychoeducational intervention for family caregivers. J Palliat Care2002; 18: 253–261.
41.
BussMKVanderwerkerLCInouyeSK, et al. Associations between caregiver-perceived delirium in patients with cancer and generalized anxiety in their caregivers. J Palliat Med2007; 10: 1083–1092.
42.
BreitbartWGibsonCTremblayA.The delirium experience: delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses/caregivers, and their nurses. Psychosomatics2002; 43(3): 183–194.
43.
BrueraEBushSHWilleyJ, et al. Impact of delirium and recall on the level of distress in patients with advanced cancer and their family caregivers. Cancer2009; 115: 2004–2012.
44.
BushSHTierneySLawlorPG.Clinical assessment and management of delirium in the palliative care setting. Drugs2017; 77: 1623–1643.
